Ascletis Pharma Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug $(IND.AU)$ application for a Phase I trial of ASC50, an oral small molecule inhibitor targeting interleukin-17 (IL-17), for the treatment of mild-to-moderate plaque psoriasis. ASC50, discovered and developed in-house by Ascletis, demonstrated favorable preclinical characteristics, including higher drug exposure, longer half-life, and lower clearance in non-human primates compared to existing oral IL-17 inhibitors. The company plans to begin dosing in the Phase I trial during the third quarter of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。